Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Mar 26, 2025
Trial Information
Current as of April 29, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a serious fungal infection called mucormycosis, which can affect patients with blood cancers (hematologic malignancies) who have received a specific type of treatment known as hematopoietic stem cell transplantation. The researchers aim to understand how the incidence, diagnosis, and treatment of mucormycosis have changed during the COVID-19 pandemic. They will look at factors like the signs and symptoms of the infection, how patients were diagnosed and treated, and the overall impact on healthcare costs. This information will help improve care for future patients undergoing stem cell transplants who may develop mucormycosis.
To be eligible for this study, participants must be at least 18 years old and have received a stem cell transplant at the study center between January 2015 and December 2023. They must also have a confirmed diagnosis of mucormycosis. Participation involves reviewing medical records, so patients or their authorized representatives will need to agree to take part and provide consent. It's important to note that patients with other types of fungal infections will not be included in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with hematologic diseases who undergoes hematopoietic stem cell transplantation in the center from January 2015 to December 2023.
- • 2. Age≥18 years old.
- • 3. Patients who were diagnosed with mucormycosis(proven or probable) in accordance with the 2008 EORTC/MSG criteria and Revised EORTC/MSGERC 2020 Criteria.\[8\]\[9\].
- • 4. The patients themselves or their authorized clients agree to participate in the clinical study and sign the informed consent.
- Exclusion Criteria:
- • 1. Patients with fungal infections other than mucormycosis were excluded.
About Institute Of Hematology & Blood Diseases Hospital, China
The Institute of Hematology & Blood Diseases Hospital in China is a leading clinical research institution specializing in hematology and related disorders. Renowned for its commitment to advancing medical knowledge and improving patient care, the Institute conducts innovative clinical trials aimed at developing novel therapies and treatment protocols. With a multidisciplinary team of experts, state-of-the-art facilities, and a robust ethical framework, the Institute is dedicated to enhancing the understanding and management of blood diseases, contributing significantly to global hematological research and patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported